Tuesday, January 22nd 2002
and welcome remarks by:
· Hervé de Kergrohen, Chairman, Biodata
· Carlo Lamprecht, Minister of Economic Affairs, State of Geneva
Proteomics, Disease, Drug Efficacy : where will we be in 5 years from now?
Predictive medicine: timing, issues and opportunities - a review of financial, ethical, and scientific issues
Group 1: Genomics/Proteomics
Group 2: Drug development
Group 3: Vaccines
The emergence of artificial intelligence: what will it mean for the life sciences industry in the next few years?
Pathogen inactivation in biological products: where do we stand?
Convergence of Biotechnology and Informatics: speeding up drug discovery
Group 4: Bioinformatics
Group 5: Drug Development
Group 6: Genomics/Proteomics
Compaq Satellite Meetin
Future directions in life Sciences from Compaq
Wednesday, January 23rd 2002
Biotech and pharmaceutical collaboration: elements for success
The biotech companies that you need to follow in 2002 and beyond
Group 7: BioPharmaceuticals
Group 8: Pre-IPO companies
Group 9: Drug Development
"Progress in prion research: can we be reassured?"
Group 10: Med Tech
Group 11: Drug Development
Group 12: Drug Development
Roundtable Discussion 4
"Can Switzerlands attractiveness for the biotechnology industry be a model for other countries?"
The "individual of the year for Switzerland" awarded by L'Agefi